Nano Science and Technology Institute

Nano-Enabled Drug Candidate Receives Initial FDA Approval

Calando Pharmaceuticals recently announced that the FDA has approved its investigational new drug application for its anti-cancer compound, CALAA-01. The company’s drug is a targeted nanoparticle delivered via its proprietary polymer delivery system. The FDA has approved a Phase I trial that will be conducted at the UCLA Jonsson Cancer Center (UCLA) in Los Angeles, California, and the South Texas Accelerated Research Therapeutics (START) clinic in San Antonio, Texas. The clinical trials will be co-led by Dr. Antoni Ribas (UCLA) and Dr. Anthony Tolcher (START).

↑ Back to Nano World Breaking News™

↑ Back to Nano World News™

Nano World News™ Issue Archive:

RSS feed RSS feed

© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map